Research Store

Research Store

Research Store
add to cart Register yourself and then log-in with your user ID and password, before clicking on 'Add to Cart'
    
Issue Date:Jun 13 2017 12:00AM     Price in Rs. R 6500    Price in USD. $ 100
    

Macleods Pharmaceuticals Ltd, was incorporated in 1986, and since then, it has made rapid progress in both domestic and the international market. Especially in the recent years, it has grown at an average growth rate of over 22% for the past 5 years. Based out of Mumbai, it has an employee base of more than 10,000 people.

India
In the domestic formulations market, Macleods enjoys a very strong position, and features amongst top 10 companies in India and is recognized as one of the fastest growing companies. It's market share in the domestic market is around 2.8%.

In the domestic business, Macleods has a very strong position in the systemic anti-bacterial segment. Among its top 10 brands, 5 are systemic anti-bacterial. Some of these brands are Cefolac, Meromac, Macpod, Oflomac. However, its top selling brand is systemic corticosteroid, which is Omnacortil. Its other brands in the top 10 are, anti-tubercuolsis (Forecox), mineral supplements (Bio D3 Plus).

It's total portfolio in the domestic market, consists of more than 600 products.

International Business
Company has expanded its international footprints tremendously in the international market as well. Currently it has presence in more than 80 countries, and across South East Asia, Asia Pacific, Africa, North America, EU & EEA, MENA, Latin America and CIS countries.

In US market, Macleods has received FDA approval on 9 Abbreviated New Drug Applications and has another 60 filed and awaiting approval.

R&D
It is also one of the core strength of the company. It's R&D centre, located in Mumbai, became functional in the year 2000, is approved by the Department of Scientific and Industrial Research, Govt. of India, and has 700 highly qualified scientists.

In the R&D Centre, varied range of work takes:
Chemical Research & Development:
The API process development division is an integral component of R & D Centre. It can handle multi-step chemical synthesis involving reaction types like, Catalytic Hydrogenation & Hydride Reductions, Heterocyclic & Amino-acid Synthesis, and Optical Resolution & Reactions involving the use of Chiral Substrates.

Formulation Development:
Here most of the work is focussed around NDDS like Immediate release tablets, Delayed release tablets, Extended release tablets, Hard gelatin Capsules, Soft gelatin capsules, Dry powder inhalers, Liquid orals, Semi solids, etc.

Other focus ares are Analytical Research & Development and Bioequivalence Study Centre

Our clinical and bio-analytical facilities and processes, have been inspected by the DCGI, US FDA, WHO and MCC (South Africa), signifying great quality standards.

Manufacturing
Company facilities are approved by international regulatory agencies including USFDA, UK-MHRA, WHO-Geneva, MCC South Africa, MOH - Saudi Arabia, MOH- UAE, MOH- Belarus, MOH- Ukraine, INVIMA- Colombia, National Drugs Authority (NDA) Uganda, Food and Drugs Board, Kenya; Pharmacy Board, Tanzania FDA, etc.

It has 2 finished dosage plant at Baddi and Daman and one API plant at Valsad

Macleods currently makes a large portion of the active ingredients that make up its products and has manufacturing capacity of over 8.0 billion tablets and capsules. Manufacturing is being expanded to include Soft gels, Topicals, Metered Dose inhalation products and liquid injectables.

Financials
In the FY2016, it clocked the total revenue of over Rs. 4027 crore with operating profit amounting to Rs.756 crore. Other income was about Rs. 133 crore. With Interest and Depreciation at Rs. 5 crore and Rs. 53 crore respectively, PBT was Rs. 831 crore. PAT was around Rs. 646 crore. Total debt in FY16 stood at Rs. 185 crore.

  1. Company Background
  2. Business Highlights
  3. Financial Performance
  4. Financial Details

 

  1. Board of Directors
  2. Financial Summary
  3. Profit & Loss Account
  4. Balance Sheet
  5. Ratios

 

Macleods Pharmaceuticals Ltd